Generate Biomedicines (NASDAQ:GENB) Shares Gap Up – Here’s What Happened

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $13.02, but opened at $13.62. Generate Biomedicines shares last traded at $13.5090, with a volume of 212,549 shares changing hands.

Analysts Set New Price Targets

Several research firms recently weighed in on GENB. HC Wainwright increased their price target on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th. The Goldman Sachs Group began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target on the stock. Cantor Fitzgerald began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating on the stock. Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Morgan Stanley increased their price target on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Generate Biomedicines presently has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Stock Up 4.9%

The company’s 50 day simple moving average is $12.94.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.